PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• "Moderate Buy" consensus from six analysts (five buys, one sell) with an average 1‑year price target of $12.25; HC Wainwright reiterated a $13 target while Weiss Ratings recently downgraded the stock.
• Shares trade near $4.43 with a market cap of about $84.5M and a 1‑year range of $2.44–$5.12; the company reported a quarterly loss of $0.41 per share (missing estimates) and sell‑side forecasts around −1.5 EPS for the year.
• Institutional investors have been active—AIGH Capital increased its stake to 1.34M shares and several firms initiated or boosted positions, leaving institutions with roughly 26.5% ownership.

PolyPid Ltd. (NASDAQ:PYPD - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $12.25.

Several research firms recently commented on PYPD. Weiss Ratings downgraded shares of PolyPid from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, May 1st. HC Wainwright reissued a "buy" rating and issued a $13.00 price objective on shares of PolyPid in a report on Wednesday, February 11th. Finally, Wall Street Zen upgraded shares of PolyPid from a "sell" rating to a "hold" rating in a research report on Saturday, March 14th.

PolyPid Trading Down 1.1%

NASDAQ:PYPD opened at $4.43 on Friday. The stock has a 50 day simple moving average of $4.38 and a 200 day simple moving average of $4.20. The stock has a market cap of $84.52 million, a P/E ratio of -1.96 and a beta of 1.41. PolyPid has a 1-year low of $2.44 and a 1-year high of $5.12.

PolyPid (NASDAQ:PYPD - Get Free Report) last posted its quarterly earnings data on Wednesday, February 11th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.07). As a group, sell-side analysts forecast that PolyPid will post -1.5 EPS for the current year.

Institutional Investors Weigh In On PolyPid

Several institutional investors have recently made changes to their positions in PYPD. AIGH Capital Management LLC lifted its holdings in shares of PolyPid by 26.1% during the 4th quarter. AIGH Capital Management LLC now owns 1,342,972 shares of the company's stock worth $5,828,000 after acquiring an additional 277,844 shares during the period. ADAR1 Capital Management LLC bought a new stake in shares of PolyPid during the 4th quarter worth approximately $451,000. Jane Street Group LLC bought a new stake in shares of PolyPid during the 4th quarter worth approximately $66,000. XTX Topco Ltd lifted its holdings in shares of PolyPid by 50.0% during the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company's stock worth $142,000 after acquiring an additional 10,888 shares during the period. Finally, HighTower Advisors LLC bought a new stake in shares of PolyPid during the 4th quarter worth approximately $44,000. 26.47% of the stock is currently owned by institutional investors.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.